source
- Zealand Pharma partners with Generate Biomedicines on multispecific obesity proteins in $1.2B dealZealand Pharma has agreed to pay Generate Biomedicines $30 million up front to start work on multispecific protein drug candidates aimed at obesity and other metabolic disorders. The agreement inc…
- FDA proposes new framework prioritizing consistency over flexibility for rare disease drug reviewsThe FDA announced a shift in its approach to evaluating rare disease therapies, emphasizing a more uniform assessment process. Agency officials explained that the flexibility shown over the summer…